Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2020-03-30 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
关于公司计提商誉减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the company's decision to make goodwill impairment provisions. It details the background of goodwill arising from acquisitions, the evaluation reports used to assess impairment, the amount of impairment recognized, and the impact on the company's financial results for the year ended December 31, 2019. The document includes board and independent directors' opinions on the reasonableness of the impairment. The length is 3121 characters, which is relatively short and the document is an announcement of the impairment provision decision rather than a full financial report. It does not contain full financial statements or comprehensive financial data but rather a specific accounting event disclosure. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about an accounting matter and goodwill impairment, not a full audit report or annual/interim report.
2020-03-30 Chinese
2019年度控股股东及其他关联方资金占用情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a special statement regarding the use of funds by controlling shareholders and related parties for the fiscal year 2019 of Jinling Pharmaceutical Co., Ltd. It includes detailed financial data such as balances, amounts, and interest related to funds occupied by related parties. The document is issued by an accounting firm and references an audit report number, indicating it is a standalone audit-related report focusing on related party fund occupation. It is not a full annual report, nor a brief announcement or certification. The content aligns with an Audit Report / Information filing, as it provides audit-related financial information and a special explanation on a specific financial matter. FY 2019
2020-03-30 Chinese
第七届董事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 20th meeting of the 7th Board of Directors of Jinling Pharmaceutical Co., Ltd. It includes voting results on various reports and proposals such as the 2019 President's Work Report, Board Work Report, Financial Statements, Profit Distribution Plan, Internal Control Self-Evaluation Report, Social Responsibility Report, appointment of auditors, accounting policy changes, goodwill impairment, related party transactions, investment in subsidiaries, and other corporate governance matters. The document repeatedly states that these reports and proposals will be submitted to the shareholders' meeting for approval and that the full reports are available on the designated website or newspapers. The document itself does not contain the full annual report or financial statements but is a formal announcement of board meeting resolutions and related corporate governance decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document is not the full Annual Report (10-K) or Audit Report (AR), nor is it a simple announcement of report publication (RPA) because it contains substantive board meeting decisions and voting results. Therefore, the correct classification is MANG with high confidence.
2020-03-30 Chinese
独立董事2019年度述职报告（王广基）
Management Reports Classification · 95% confidence The document is titled as an "Independent Director 2019 Annual Report" and details the independent director's activities, attendance at board meetings, opinions expressed, committee work, and efforts to protect shareholder rights during the 2019 fiscal year. It is a narrative report on the director's duties and performance rather than a financial report or announcement. The document length is 2072 characters, which is relatively short but contains substantive content about the director's role and activities. This fits best with a Management Reports (MDA) classification, as it is a detailed explanation of management-related activities and governance from the perspective of an independent director. It is not an announcement of voting results, not a full annual report, nor a regulatory filing or certification. Therefore, the most appropriate classification is MDA with high confidence.
2020-03-30 Chinese
董事会关于2019年度证券投资情况的专项说明
Regulatory Filings Classification · 95% confidence The document is a special explanation by the board of directors of Jinling Pharmaceutical Co., Ltd. regarding the company's securities investment situation for the year 2019. It includes detailed financial figures about securities investments, investment income, and internal control measures related to securities investments. The document references quarterly and half-year reports where these matters were disclosed but itself is a focused explanation on securities investment rather than a full annual or interim financial report. The length is 1773 characters, which is relatively short and the document is not a full financial report but a specific disclosure. It does not fit the categories of Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is not a regulatory filing or certification. It is a special statement on securities investment by the board, which aligns best with a Regulatory Filing (RNS) as a miscellaneous disclosure that does not fit other categories.
2020-03-30 Chinese
2019年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the 2019 annual financial settlement report of Jinling Pharmaceutical Co., Ltd. It includes detailed financial statements, analysis of assets, liabilities, equity, income, expenses, profit, and changes in accounting policies. It also references an audit report issued by Tianheng Accounting Firm, confirming the financial statements' compliance with accounting standards. The document contains comprehensive financial data for the full fiscal year 2019, including consolidated and parent company financials, changes in subsidiaries, and detailed financial metrics. The length of the document (8134 characters) and the presence of substantive financial data confirm it is the full annual report rather than a brief announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2019
2020-03-30 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.